Harnessing Recent Advances in Synthetic DNA and Electroporation Technologies for Rapid Vaccine Development Against COVID-19 and Other Emerging Infectious Diseases
Open Access
- 21 October 2020
- journal article
- review article
- Published by Frontiers Media SA in Frontiers in Medical Technology
- Vol. 2, 571030
- https://doi.org/10.3389/fmedt.2020.571030
Abstract
DNA vaccines are considered as a third-generation vaccination approach in which antigenic materials are encoded as DNA plasmids for direct in vivo production to elicit adaptive immunity. As compared to other platforms, DNA vaccination is considered to have a strong safety profile, as DNA plasmids neither replicate nor elicit vector-directed immune responses in hosts. While earlier work found the immune responses induced by DNA vaccines to be sub-optimal in larger mammals and humans, recent developments in key synthetic DNA and electroporation delivery technologies have now allowed DNA vaccines to elicit significantly more potent and consistent responses in several clinical studies. This paper will review findings from the recent clinical and preclinical studies on DNA vaccines targeting emerging infectious diseases (EID) including COVID-19 caused by the SARS-CoV-2 virus, and the technological advancements pivotal to the improved responses—including the use of the advanced delivery technology, DNA-encoded cytokine/mucosal adjuvants, and innovative concepts in immunogen design. With continuous advancement over the past three decades, the DNA approach is now poised to develop vaccines against COVID-19, as well as other EIDs.Funding Information
- National Institutes of Health (U19 Al109646-04)
This publication has 148 references indexed in Scilit:
- Influenza Virus H5 DNA Vaccination Is Immunogenic by Intramuscular and Intradermal Routes in HumansClinical and Vaccine Immunology, 2012
- Intranasal DNA Vaccination Induces Potent Mucosal and Systemic Immune Responses and Cross-protective Immunity Against Influenza VirusesMolecular Therapy, 2011
- A SARS DNA vaccine induces neutralizing antibody and cellular immune responses in healthy adults in a Phase I clinical trialVaccine, 2008
- DNA vaccines: ready for prime time?Nature Reviews Genetics, 2008
- Heterologous HA DNA vaccine prime—inactivated influenza vaccine boost is more effective than using DNA or inactivated vaccine alone in eliciting antibody responses against H1 or H3 serotype influenza virusesVaccine, 2008
- Safety and Immunogenicity of a Bivalent Cytomegalovirus DNA Vaccine in Healthy Adult SubjectsThe Journal of Infectious Diseases, 2008
- Global trends in emerging infectious diseasesNature, 2008
- Induction of Specific Immune Responses by Severe Acute Respiratory Syndrome Coronavirus Spike DNA Vaccine with or without Interleukin-2 Immunization Using Different Vaccination Routes in MiceClinical and Vaccine Immunology, 2007
- A DNA Prime-Modified Vaccinia Virus Ankara Boost Vaccine Encoding Thrombospondin-Related Adhesion Protein but Not Circumsporozoite Protein Partially Protects Healthy Malaria-Naive Adults against Plasmodium falciparum Sporozoite ChallengeInfection and Immunity, 2006
- A DNA vaccine induces SARS coronavirus neutralization and protective immunity in miceNature, 2004